Recurrent Endometrial Carcinoma Completed Phase 2 Trials for Lapatinib (DB01259)

Also known as: Endometrial Carcinoma, Recurrent

IndicationStatusPhase
DBCOND0028796 (Recurrent Endometrial Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00096447Lapatinib in Treating Patients With Recurrent or Persistent Endometrial CancerTreatment